BIOTECH LOTTERY: GENMAB +39%, CG ONCOLOGY +15% TODAY, AND 7 NAMES GETTING DUMPED Biotech is splitting into winners and losers. Genmab is up 39% in a month on oncology data, and CG Oncology jumped 15% today on positive Phase 3 bladder-cancer data. Absci, Ginkgo and Summit all sold off. Here are the catalysts and the head-to-heads. +39% in 30 days for $GMAB. +15.6% today for $CGON. Then there's the other side: $ABSI -12.7%, $DNA -9.6%, $SMMT -9.4%. Biotech's best and worst setups right now 👇 1) $GMAB Genmab: Genmab (GMAB) shares climbed roughly 39% over the last 30 days, rising from about $36.89 to $51.36 as of the latest close, driven by a sequence of positive late-stage oncology readouts. https://t.co/PYnE76VkRc 2) $CGON CG Oncology: CG Oncology shares rose to $86.02 from Friday's $74.40 close, a gain of +$11.62, or +15.62%, with the move occurring during Monday's regular session. The catalyst was the 8:00 a.m. ET release of positive Phase 3 PIVOT-006 topline data: adjuvant cretostimogene cut bladder cancer recurrence risk by 68% versus control (hazard ratio 0.32, p<0.0001) in intermediate-risk and high-grade Ta NMIBC, well above the... https://t.co/AatDYg5am6 3) $ABSI Absci: ABSI dropped -12.66% from Friday's $8.45 close to $7.38, with the decline occurring in premarket trading before the regular session opened near $7.39; the stock sits roughly -22% lower over the past week. No single fundamental catalyst explains a drop of this size: the only same-day item was Guggenheim trimming its target to $14 from $15 while keeping a Buy, a technical model adjustment too small to... https://t.co/hXXrvBMNnn 4) $DNA Ginkgo Bioworks: DNA dropped -9.57% to $8.69 from Friday's close of $9.61, with the decline occurring during Monday's regular session after premarket weakness near $9.21. No verified news or fundamental catalyst found; the move is consistent with continued profit-taking that has now wiped out the post-earnings rally, with shares sliding for a fourth straight session from $12.37 on Nov. 9 — a stock that typically swings... https://t.co/Jl3UwycwZN 5) $SMMT Summit Therapeutics: SMMT dropped from Friday's $14.15 close to $12.82, a -9.40% decline, after gapping sharply lower in premarket trading and extending losses in Monday's regular session. The trigger was a weekend FDA complete response letter rejecting Summit's BLA for ivonescimab plus platinum chemotherapy in EGFR-mutated non-small cell lung cancer after prior TKI therapy, with the agency citing no statistically significant... https://t.co/l3lM6WApL3 6) $TWST Twist Bioscience: Twist Bioscience shares dropped -7.11% to $103.67 in early regular-session trading on Monday, falling from Friday's close of $111.60. The slide extended a post-earnings selloff after a fresh round of analyst price-target cuts: Barclays lowered its target to $130 from $215 Monday morning, following UBS's overnight cut to $120 from $190, with both firms citing a premium valuation and a higher bar after... https://t.co/Kto4qAdIAZ 7) $CAPR Capricor Therapeutics: Capricor Therapeutics (CAPR) fell -5.56% to $9.00 from Friday's close of $9.53, a regular-session decline that opened at $9.21 and slid as low as $8.57 before stabilizing. The drop followed Summit Therapeutics' weekend FDA complete response letter for ivonescimab, which sent SMMT down -9.89% and reinforced regulatory caution across clinical-stage biotech days before CAPR's own deramiocel decision, due Nov. 22. https://t.co/pVnWSoyOL2 8) $AAPG Ascentage Pharma Group International: AAPG fell -6.70%, from a $14.62 close on Nov 13 to $13.64, sliding in premarket and extending losses into early regular-session trading on Monday. No verified news or fundamental catalyst found; the drop is likely technical, tracking the -7.05% decline in the company's Hong Kong-listed shares hours earlier, a pattern consistent with a thinly traded micro-cap that averages a ~3.0% daily swing. https://t.co/G2ZOFqZFGE 9) $KRRO Korro Bio: KRRO fell -3.01% during Monday's regular session, sliding from Friday's $13.61 close to $13.20 by mid-morning, with no meaningful premarket gap. No verified news or fundamental catalyst found. https://t.co/cw0ayQIwTU 10) $CG vs $CGON: Weighing Biotech Catalysts in Different Disease Areas. Two setups, one head-to-head. Which one comes out ahead? The breakdown is in the link. https://t.co/N5emYPTx98 11) $CGON vs $IDYA: Weighing Two Oncology Biotech Names in a Catalyst-Driven Sector. Two setups, one head-to-head. Which one comes out ahead? The breakdown is in the link. https://t.co/rLT3ER4K1K 12) $CGON vs $LXEO: Weighing Late-Stage Stability Against Early-Stage Gene Therapy Upside. Two setups, one head-to-head. Which one comes out ahead? The breakdown is in the link. https://t.co/FDd6QQNu8N Full numbers, catalysts and risks are in each link. Which one are you opening first? Figures are from today's (Nov 16) write-ups, using intraday or latest-close prices, not live quotes. Price targets are targets, not promises. Not investment advice. #biotech #stocks #oncology #FDA #healthcare #StockMarket
TickeronShare

Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.